How long does B12 repletion take, including neurological recovery?

How it works

Once supplementation is ongoing, serum B12 rises mechanically with the dose regardless of whether tissues are using it; this is why serum B12 alone is unreliable as a response marker in the maintenance phase. Functional markers (MMA, homocysteine) reflect cellular utilisation more directly. The 120-day RBC lifespan also means existing macrocytic red cells must be replaced through natural turnover before MCV fully normalises.

Effective dose

Reassessment at 3 months: clinical symptom review, FBC including reticulocyte count and MCV trajectory, ferritin, MMA if available and clinically indicated. Re-checking serum B12 alone at 3 months is not informative once supplementation is ongoing. Lifelong injection therapy users (pernicious anaemia, post-gastrectomy): routine ongoing serum B12 monitoring is not recommended; clinical review at maintenance schedule (every 2-3 months) suffices.

Forms compared

Haematological markers (FBC): reticulocyte count is the earliest objective response marker; hypersegmented neutrophils, MCV, and haemoglobin reflect different recovery timelines. Iron studies (ferritin, transferrin saturation): should be co-checked because iron deficiency commonly coexists especially in vegan, gastric-atrophic, or post-bariatric users and can mask the macrocytic picture. LDH and unconjugated bilirubin: raised in untreated megaloblastic anaemia from ineffective erythropoiesis; normalise over weeks.

Timing

LDH and unconjugated bilirubin: normalise over weeks. Severe and long-standing subacute combined degeneration may not fully reverse; duration of deficiency before therapy is the strongest predictor of recovery completeness. Patients on oral therapy: review adherence, symptoms, and consider MMA if response uncertain. Long-standing peripheral neuropathy can take 6-12 months to partially resolve.

Safety profile

Folate alone can normalise the macrocytic blood picture of B12 deficiency without correcting the B12-dependent neurological pathways, allowing irreversible neurological damage to progress while the blood count looks improved (Stabler 2013 NEJM). Where both B12 and folate are deficient, B12 must be addressed first or in parallel. Renal function affects MMA interpretation: chronic kidney disease raises MMA and homocysteine independently and modifies B-vitamin therapy risk-benefit (Spence and Hankey 2017 Lancet Neurol IPD meta of VISP and VITATOPS, DOI 10.1016/S1474-4422(17)30180-1).

Special populations

Pregnancy: B12 deficiency has implications for neural tube development alongside folate; standard antenatal screening per NICE. Breastfeeding mothers who are vegan: ensure adequate B12 supplementation (infant B12 deficiency can develop). Long-term metformin, PPI, or H2 receptor antagonist users: monitor for B12 deficiency over years; consider MMA testing if symptoms develop. Anticonvulsant users (pregabalin, primidone, phenytoin): may affect B12 status.

Interactions

Folate co-supplementation during acute B12 repletion: folic acid 5 mg/day for 4 weeks is sometimes added to address functional folate deficiency from accelerated red cell production, but B12 must be confirmed and repletion started first or alongside. Renal function: CKD raises MMA and homocysteine independently and modifies B-vitamin therapy risk-benefit per Spence and Hankey 2017.

Guideline positions

NICE NG239 codifies the principle that B12 repletion must not be delayed pending test results when neurological symptoms are present. NICE NG239 recommends MMA testing in selected cases. Underlying cause workup: intrinsic factor antibodies (high specificity, low sensitivity for pernicious anaemia); parietal cell antibodies (higher sensitivity for autoimmune gastritis but less specific); coeliac serology (anti-tissue-transglutaminase IgA with total IgA to interpret); medication review; renal function; consideration of post-gastrectomy or terminal-ileal-resection history; dietary assessment.

Practical framework

Common explanations for poor response: coexistent iron deficiency limiting erythropoiesis; coexistent folate deficiency; underlying haemoglobinopathy; chronic inflammation (anaemia of inflammation); misdiagnosis (particularly if serum B12 was borderline or active B12 was not measured); non-adherence (oral) or missed injections; rare hereditary cobalamin metabolism disorders. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

Common misconceptions

Claim: failure of haemoglobin rise after 4-8 weeks of B12 means the diagnosis was wrong. Coexistent iron deficiency, folate deficiency, haemoglobinopathy, chronic inflammation, or non-adherence can all blunt the response; reconsidering the diagnosis is one option among several.

Claim: MCV normalising fast indicates good response. MCV takes 3-4 months to fully normalise reflecting the 120-day RBC lifespan; faster normalisation may indicate coexistent iron deficiency masking the macrocytic picture.

Claim: long-standing neurological signs always reverse with adequate replacement. Severe and long-standing subacute combined degeneration may not fully reverse.